Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumor in adults with a median survival of 16.2–21.2 months post diagnosis (Stupp et al., N Engl J Med 352(10): 987–996, 2005). Because of its location, complete surgical resection is impossible; additionally because GBM is also resistant to chemotherapeutic and radiotherapy approaches, development of novel therapies is urgently needed. In this chapter we describe the development of preclinical animal models and a conditionally cytotoxic and immune-stimulatory gene therapy strategy that successfully causes tumor regression in several rodent GBM models.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Candolfi M et al (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J Neurooncol 85(2):133–148
Castro MG et al (2011) Gene therapy and targeted toxins for glioma. Curr Gene Ther 11(3):155–180
King GD et al (2005) Gene therapy and targeted toxins for glioma. Curr Gene Ther 5(6):535–557
Radaelli E et al (2009) Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease. Histol Histopathol 24(7):879–891
Baker GJ et al (2014) Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia 16(7):543–561
Assi H et al (2012) Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett 527(2):71–77
Finsen B, Owens T (2011) Innate immune responses in central nervous system inflammation. FEBS Lett 585(23):3806–3812
Fabry Z et al (2008) Sensing the microenvironment of the central nervous system: immune cells in the central nervous system and their pharmacological manipulation. Curr Opin Pharmacol 8(4):496–507
Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous system. J Clin Invest 122(4):1164–1171
Ali S et al (2005) Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65(16):7194–7204
Curtin JF et al (2005) Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr Top Med Chem 5(12):1151–1170
Ghulam Muhammad AK et al (2009) Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression. Clin Cancer Res 15(19):6113–6127
Curtin JF et al (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med 6(1):e10
Akli S et al (1993) Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 3(3):224–228
Le Gal La Salle G et al (1993) An adenovirus vector for gene transfer into neurons and glia in the brain. Science 259(5097):988–990
Southgate T et al (2008) Gene transfer into neural cells in vitro using adenoviral vectors. Curr Protoc Neurosci. Chapter 4: p. Unit 4 23
Barcia C et al (2006) Immunological thresholds in neurological gene therapy: highly efficient elimination of transduced cells might be related to the specific formation of immunological synapses between T cells and virus-infected brain cells. Neuron Glia Biol 2(4):309–322
Ng P, Graham FL (2002) Construction of first-generation adenoviral vectors. Methods Mol Med 69:389–414
Bett AJ et al (1994) An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 91(19):8802–8806
Thomas CE et al (2001) Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain. Mol Ther 3(1):36–46
Kreppel F et al (2002) Long-term transgene expression in the RPE after gene transfer with a high-capacity adenoviral vector. Invest Ophthalmol Vis Sci 43(6):1965–1970
King GD et al (2008) High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol 82(9):4680–4684
Puntel M et al (2010) Gene transfer into rat brain using adenoviral vectors. Curr Protoc Neurosci. Chapter 4: p. Unit 4 24
Glover CP et al (2003) Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used. J Gene Med 5(7):554–559
Candolfi M et al (2011) B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 13(10):947–960
Candolfi M et al (2014) Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models. Clin Cancer Res 20(6):1555–1565
King GD et al (2011) Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. Mol Ther 19(10):1793–1801
Mineharu Y et al (2014) Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions. Mol Cancer Ther 13(12):3024–3036
Mineharu Y et al (2011) Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design. Clin Cancer Res 17(14):4705–4718
Acknowledgements
This work was supported by National Institutes of Health/National Institute of Neurological Disorders & Stroke (NIH/NINDS) Grants U01-NS052465, U01-NS052465-S1, R01-NS074387, and R01-NS057711 to M.G.C.; NIH/NINDS Grants R01-NS054193, R01-NS061107, R01-NS082311, and R21-NS084275 to P.R.L.; the Department of Neurosurgery, University of Michigan School of Medicine; the Michigan Institute for Clinical and Health Research, NIH 2UL1-TR000433; University of Michigan Cancer Biology Training Grant, NIH/NCI (National Cancer Institute) T32-CA009676; University of Michigan Training in Clinical and Basic Neuroscience, NIH/NINDS T32-NS007222; and the University of Michigan Medical Scientist Training Program, NIH/NIGMS (National Institute of General Medicine Sciences) T32-GM007863. M.C. and M.A.M.A were supported by the Consejo Nacional de Ciencia y Tecnologia (CONICET PIP 114-201101-00353) and the Agencia Nacional de Promocion Cientifica y Tecnologica (PICT-2012-0830 and PICT-2013-0310).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Kamran, N. et al. (2016). Gene Therapy for the Treatment of Neurological Disorders: Central Nervous System Neoplasms. In: Manfredsson, F. (eds) Gene Therapy for Neurological Disorders. Methods in Molecular Biology, vol 1382. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3271-9_31
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3271-9_31
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3270-2
Online ISBN: 978-1-4939-3271-9
eBook Packages: Springer Protocols